Replies to post #441456 on NorthWest Biotherapeutics Inc (NWBO)

[jondoeuk]

Those type of tumors are homogeneous vs heterogenous.

Patients can still relapse, one reason is due to CD19 negative disease. GILD and others are moving forward dual targeting CAR-T's https://cancerimmunolres.aacrjournals.org/content/4/6/498.long

DCVAX theoretically fixes this challenge. Fully personalized to the tumor itself.

There is a reason why the likes of BNTX/RHHBY, GRTS, GNCA and MRNA/MRK are selecting which neoantigens to target with their vaccines.

Start at minute 5. "if you think about the heterogeneity of the disease... no one should be surprised that these previous immunotherapies didn't work" -paraphrasing but..

Yes, it has been know what the mutations vary from cell to cell, tumour to tumour, and patient to patient, even when it is the same type and stage https://www.nejm.org/doi/full/10.1056/nejmoa1113205